Drug Trial Radar · NCT05194995
JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
Last checked: Nov 20, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
48
Actual
Start
Feb 17, 2022
Primary completion
Apr 30, 2025
Study completion Dec 2026
Sponsor
- Lead sponsor
- Allist Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 18, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the safety, tolerability, pharmacokinetics and antitumor activity of JAB-21822 in combination with cetuximab in patients with advanced colorectal cancer,advanced small intestine cancer and advanced appendiceal cancer with KRAS p.G12C mutation.
Conditions
- Advanced Colorectal Cancer
- Small Intestinal Cancer
- Appendiceal Cancer
Interventions
JAB-21822Drug
JAB-21822 administered orally as a tablet.
CetuximabDrug
Cetuximab administered as an intravenous (IV) infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation phase: Number of participants with dose-limiting toxicities (DLTs)Time frame: At the end of Cycle 1 (each cycle is 21 days)
- Dose Expansion phase: Overall response rate (ORR)Time frame: Up to 4 years - from baseline to RECIST confirmed Progressive Disease
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Research site31
Beijing, Beijing Municipality, China
Research site01
Beijing, Beijing Municipality, China
Research site02
Beijing, Beijing Municipality, China
Research site12
Beijing, Beijing Municipality, China
Research site13
Nanning, Guangxi, China
Research site06
Harbin, Heilongjiang, China
Research site05
Zhengzhou, Henan, China
Research site07
Zhengzhou, Henan, China
Research site18
Wuhan, Hubei, China
Research site11
Changsha, Hunan, China
Research site29
Changsha, Hunan, China
Research site09
Nanjing, Jiangsu, China
Research site08
Nanchang, Jiangxi, China
Research site16
Linyi, Shandong, China
Research site28
Shanghai, Shanghai Municipality, China
Research site23
Xi’an, Shanxi, China
Research site19
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.